"The launch of the generic versions of Axiron® made it no longer commercially viable to market Axiron® in the US, and the product was withdrawn from the US market on 5th September 2017"
so I guess reducing the price and meeting the challenge of the generics headon was not an option??. more to this then meets the eye IMO - wonder if condition of Eli agreement dissolution was that ACR was unable to market its product in a generic form??
transparency just like the Hexima matter hey!!!
"The launch of the generic versions of Axiron® made it no longer...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.89M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3903 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.4¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable